Drug Trial Radar · NCT03403205
Efficacy and Safety of ALXN1840 Administered for 48 Weeks Versus Standard of Care in Participants With Wilson Disease
Last checked: Nov 20, 2026Latest source record: Jun 17, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
214
Actual
Start
Feb 22, 2018
Primary completion
Jun 30, 2023
Study completion Jun 30, 2023
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 18, 2018
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the efficacy and safety of ALXN1840 (formerly called WTX101) administered for 48 weeks compared to standard of care (SoC) in Wilson Disease (WD) participants aged 12 and older in the Primary Evaluation Period. In addition, efficacy and safety will be evaluated during an optional 60-month Extension Period.
Conditions
- Wilson Disease
Interventions
ALXN1840Drug
ALXN1840 administered orally in 15 mg tablets
SoC TherapyDrug
Depending on the site/region, participants randomized to receive SoC treatment will receive trientine, penicillamine, Zinc, or a combination of these medicines, administered according to standard regimens.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Daily Mean Area Under The Effect-time Curve (AUEC) of Directly Measured Non-ceruloplasmin-bound Copper (dNCC) From 0 to 48 Weeks (dNCC AUEC0-48W)Time frame: Baseline to Week 48
Locations
56 sites in 22 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
New Haven, Connecticut
Research Site
Chicago, Illinois
Research Site
Ann Arbor, Michigan
Research Site
Houston, Texas
Research Site
Seattle, Washington
Research Site
Adelaide, Australia
Research Site
Concord, Australia
Research Site
Parkville, Australia
Research Site
Parkville, Australia
Research Site
Graz, Austria
Research Site
Innsbruck, Austria
Research Site
Vienna, Austria
Research Site
Toronto, Ontario, Canada
Research Site
Prague, Czechia
Research Site
Århus N, Denmark
Research Site
Bron, France
Research Site
Paris, France
Research Site
Hamburg, Germany
Research Site
Heidelberg, Germany
Research Site
Leipzig, Germany
Research Site
Hong Kong, Hong Kong
Research Site
Budapest, Hungary
Research Site
Jerusalem, Israel
Research Site
Ramat Gan, Israel
Research Site
Chiba, Japan
Research Site
Kumamoto, Japan
Research Site
Kurume-shi, Japan
Research Site
Matsuyama, Japan
Research Site
Meguro-ku, Japan
Research Site
Sapporo, Japan
Research Site
Takatsuki-shi, Japan
Research Site
Yokohama, Japan
Research Site
Grafton, New Zealand
Research Site
Warsaw, Poland
Research Site
Warsaw, Poland
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Moscow, Russia
Research Site
Nizhny Novgorod, Russia
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.